

Appendix 4C



ASX Release

Appendix 4C – Q3 2019 Quarterly Cash Flow Report

31st October 2019 – Sydney, Australia– Oneview Healthcare PLC (ASX:ONE) today released its Appendix 4C – Quarterly Cashflow report for the period ending 30th September 2019.

Financial Highlights

Operating cash net outflows for the quarter were €4.29 million (compared to €4.28 million the previous quarter) which included:

- Receipts from customers of €2.65 million. As per the announcement of 4th October, certain anticipated hardware orders have been delayed impacting both total revenue and cash receipts;
- Payments for staff costs in the quarter of €4.1 million, which included €503k in short-term contract engineering costs associated with the imminent delivery of the Senior Living product which is to be delivered in Q4. The Company expects these costs to be reduced from Q1 20 as development of this product will be substantially complete. The company expects average quarterly staff costs for 2020 of €3.0m per quarter;
- Administration and corporate costs of €0.9 million. The Company has reduced its office occupancy costs surrendering its lease on its former Dublin office space in the quarter and this will have the impact of reducing rental and associated costs by approx. €240k on an annualized basis;
- Unrealised FX translation costs had a negative impact in the quarter of €207k.



Cash balances as at 30th Sept 2019 amounted to €13.89 million. The company's business model is predicated on a recurring revenue model. Oneview continues to aggressively manage its cost base.

Directors J Rooney (Chairman) | L Berkowitz | J Fitter | M Kaminski | M McCloskey



Unifying the care experience.

Operational Highlights

During the period, the company achieved the following operational highlights:

- Deployed 730 new live beds for the quarter;
- In Thailand, Oneview signed an agreement for Phase II (137 beds) of the rollout of its solution into Bumrungrad International Hospital, Bangkok, Thailand;
- In California, Oneview renewed its contract at the University of California, San Francisco, Mission Bay, with an agreement to upgrade the solution to the new Oneview Android platform;
- In Missouri, Oneview installed 103 beds in Barnes-Jewish West County Hospital;
- The BJC South expansion was completed and is now fully migrated to Gen 3;
- The Oneview solution went live in 2 new facilities in UCSF (PCMB and Parnassus);
- We remain in formal contract negotiations with a major provider in the age care industry for the deployment of its care management solution. Technical due diligence was completed in the quarter, delivery is on track for Q4 and we anticipate contract completion in due course.

Full time headcount at the end of September was 121 (June 2019: 127).

About Oneview Healthcare

Oneview provides interactive healthcare technologies for patients, families and caregivers. Oneview's technology weaves a facility's existing disparate systems into a single seamless platform, allowing healthcare facilities to engage patients in meaningful ways, improve communication, and streamline clinical workflows. Patients enjoy the comfort and convenience of information, education, entertainment and environmental controls at the bedside, while facilities enjoy better health outcomes and patient satisfaction.

Enquiries: James Fitter, CEO or John Kelly, CFO

Oneview Healthcare

Website : www.oneviewhealthcare.com

Directors J Rooney (Chairman) | L Berkowitz | J Fitter | M Kaminski | M McCloskey

Oneview Healthcare plc

Block 2, Blackrock Business Park, Blackrock Co. Dublin, A94 H2X4 Ireland

P +353 1 524 1677 **E** info@oneviewhealthcare.com oneviewhealthcare.com

Irish Company Reg: 513842

ARBN 610 611 768

VAT Number 9853271T

Appendix 4C

Quarterly report for entities subject to Listing Rule 4.7B

Introduced 31/03/00 Amended 30/09/01, 24/10/05, 17/12/10, 01/09/16

Name of entity

Oneview Healthcare PLC

ABN

610 611 768

Quarter ended ("current quarter")

30th September 2019

Consolidated statement of cash flows	Current quarter €'000	Year to date (9 months) €'000
1. Cash flows from operating activities		
1.1 Receipts from customers	2,651	8,462
1.2 Payments for		
(a) research and development	-	-
(b) product manufacturing and operating costs	(684)	(2,334)
(c) advertising and marketing	(159)	(397)
(d) leased assets	-	-
(e) staff costs	(4,096)	(11,832)
(f) administration and corporate costs	(898)	(2,793)
1.3 Dividends received (see note 3)	-	-
1.4 Interest received	-	-
1.5 Interest and other costs of finance paid	-	-
1.6 Income taxes paid	(29)	(74)
1.7 Government grants and tax incentives	-	-
1.8 Other – incl. general working capital movements.	(870)	(746)
- Other – FX (unrealised)	(207)	(259)
1.9 Net cash from / (used in) operating activities	(4,292)	(9,973)

2.	Cash flows from investing activities		
2.1	Payments to acquire:		
	(a) property, plant and equipment	(18)	(63)
	(b) businesses (see item 10)	-	-
	(c) investments	-	-
	(d) intellectual property	(122)	(366)
	(e) other non-current assets	-	-
2.2	Proceeds from disposal of:		
	(a) property, plant and equipment	-	-
	(b) businesses (see item 10)	-	-
	(c) investments	-	-
	(d) intellectual property	-	-
	(e) other non-current assets	-	-
2.3	Cash flows from loans to other entities	-	-
2.4	Dividends received (see note 3)	-	-
2.5	Other (provide details if material)	-	-
2.6	Net cash from / (used in) investing activities	(140)	(429)

3.	Cash flows from financing activities		
3.1	Proceeds from issues of shares	-	15,905
3.2	Proceeds from issue of convertible notes	-	-
3.3	Proceeds from exercise of share options	-	2
3.4	Transaction costs related to issues of shares, convertible notes or options	-	(1,226)
3.5	Proceeds from borrowings	-	-
3.6	Repayment of borrowings	-	-
3.7	Transaction costs related to loans and borrowings	-	-
3.8	Dividends paid	-	-
3.9	Other (provide details if material)	-	-
3.10	Net cash from / (used in) financing activities	-	14,681

4.	Net increase / (decrease) in cash and cash equivalents for the period		
4.1	Cash and cash equivalents at beginning of quarter/year to date	18,078	9,331
4.2	Net cash from / (used in) operating activities (item 1.9 above)	(4,292)	(9,973)
4.3	Net cash from / (used in) investing activities (item 2.6 above)	(140)	(429)
4.4	Net cash from / (used in) financing activities (item 3.10 above)	-	14,681
4.5	Effect of movement in exchange rates on cash held	241	277
4.6	Cash and cash equivalents at end of quarter	13,887	13,887

5.	Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current quarter €'000	Previous quarter €'000
5.1	Bank balances	13,887	18,078
5.2	Call deposits	-	-
5.3	Bank overdrafts	-	-
5.4	Other (provide details)	-	-
5.5	Cash and cash equivalents at end of quarter (should equal item 4.6 above)	13,887	18,078

6.	Payments to directors of the entity and their associates	Current quarter €'000
6.1	Aggregate amount of payments to these parties included in item 1.2	184
6.2	Aggregate amount of cash flow from loans to these parties included in item 2.3	-
6.3	Include below any explanation necessary to understand the transactions included in items 6.1 and 6.2	

7. Payments to related entities of the entity and their associates

**Current quarter
€'000**

7.1 Aggregate amount of payments to these parties included in item 1.2

-

7.2 Aggregate amount of cash flow from loans to these parties included in item 2.3

-

7.3 Include below any explanation necessary to understand the transactions included in items 7.1 and 7.2

8. Financing facilities available

Add notes as necessary for an understanding of the position

**Total facility amount
at quarter end
€'000**

**Amount drawn at
quarter end
€'000**

8.1 Loan facilities

-

-

8.2 Credit standby arrangements

-

-

8.3 Other (please specify)

-

-

8.4 Include below a description of each facility above, including the lender, interest rate and whether it is secured or unsecured. If any additional facilities have been entered into or are proposed to be entered into after quarter end, include details of those facilities as well.

9. Estimated cash outflows for next quarter

€'000

9.1 Research and development

-

9.2 Product manufacturing and operating costs

(682)

9.3 Advertising and marketing

(95)

9.4 Leased assets

-

9.5 Staff costs

(3,668)

9.6 Administration and corporate costs

(770)

9.7 Other (provide details if material)

-

9.8 Total estimated cash outflows

(5,215)

10.	Acquisitions and disposals of business entities (items 2.1(b) and 2.2(b) above)	Acquisitions	Disposals
10.1	Name of entity	-	-
10.2	Place of incorporation or registration	-	-
10.3	Consideration for acquisition or disposal	-	-
10.4	Total net assets	-	-
10.5	Nature of business	-	-

Compliance statement

- 1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
- 2 This statement gives a true and fair view of the matters disclosed.



Sign here:

Director

Date: 31 October 2019

Print name: James Fitter

Notes

1. The quarterly report provides a basis for informing the market how the entity's activities have been financed for the past quarter and the effect on its cash position. An entity that wishes to disclose additional information is encouraged to do so, in a note or notes included in or attached to this report.
2. If this quarterly report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, AASB 107: *Statement of Cash Flows* apply to this report. If this quarterly report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.